SCHEMBL8866076

SCHEMBL8866076

Cc1cccc(S(=O)(=O)c2ccc([N+](=O)[O-])cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.64
HTT P42858 2/20 0.64
GAA P10253 1/20 0.64
ACHE P22303 3/20 0.58
TSHR P16473 1/20 0.58
HSD17B10 Q99714 1/20 0.50
BCHE P06276 1/20 0.50
POLB P06746 1/20 0.49
ABCC9 O60706 1/20 0.48
ABCC8 Q09428 1/20 0.48
KCNJ11 Q14654 1/20 0.48
KCNJ8 Q15842 1/20 0.48
HSP90AA1 P07900 1/20 0.48
CXCR5 P32302 1/20 0.48
APLNR P35414 1/20 0.48
RAB9A P51151 1/20 0.48
CCR6 P51684 1/20 0.48
GFER P55789 1/20 0.48
CA2 P00918 3/20 0.47
CA5A P35218 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11841996 0.88 KMT2A (0.75) KMT2AHTTGAATSHRPOLB
SCHEMBL7142883 0.84 ACHE (0.55) KMT2AHTTGAAACHETSHR
SCHEMBL10341547 0.84 KMT2A (0.89) KMT2AHTTGAATSHRCA2
SCHEMBL15689650 0.83 KMT2A (0.64) KMT2AHTTGAATSHRPOLB
SCHEMBL8664087 0.83 KMT2A (0.80) KMT2AHTTGAAACHETSHR
SCHEMBL6151129 0.82 GAA (0.67) KMT2AHTTGAAPOLBABCC9
SCHEMBL6577803 0.82 ACHE (0.75) KMT2AGAAACHEHSD17B10BCHE
SCHEMBL31038387 0.82 GAA (0.67) KMT2AHTTGAAPOLBABCC9
SCHEMBL822302 0.82 KMT2A (0.59) KMT2AHTTGAAACHETSHR
SCHEMBL29468572 0.82 KMT2A (0.59) KMT2AHTTGAAACHETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708338-B2 Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof NEUROPORE THERAPIES, INC. (US) 2023-07-25 US disclosed
US-5684198-A N-ARYL-2-HYDROXYPROPANAMIDES IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1997-11-04 US disclosed
US-5567735-A CELL POTASSIUM CHANNEL MODULATOR FOR TREATING ASTHMA IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1996-10-22 US disclosed
US-5565477-A TREATMENT OF URINARY INCONTINENCE IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1996-10-15 US disclosed
US-5565465-A TREATMENT OF URINARY INCONTINENCE IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1996-10-15 US disclosed
EP-0524781-B1 Therapeutic amides ZENECA LTD (GB) 1996-03-27 EP disclosed
US-5474999-A Useful in treatment of urinary incontinence IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-12-12 US disclosed
US-5382598-A Therapeutic amides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-01-17 US disclosed
US-5272163-A Therapeutic amides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-12-21 US disclosed
EP-0524781-A1 Therapeutic amides ZENECA LIMITED (GB) 1993-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708338-B2 Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof TPMT, ABCB1, DPP8 KMT2A 3726/4885HTT 185/4885GAA 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.